united therapeutics corp (UTH:Frankfurt)
united therapeutics corp (UTH) Snapshot
|
Open
€52.85
|
Previous Close
€53.21
|
|
|
Day High
€52.85
|
Day Low
€52.34
|
|
|
52 Week High
05/20/13 - €53.84
|
52 Week Low
05/23/12 - €33.24
|
|
|
Market Cap
--
|
Average Volume 10 Days
14.0
|
|
|
EPS TTM
--
|
Shares Outstanding
0.0
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
united therapeutics corp (UTH) Related Businessweek News
united therapeutics corp (UTH) Details
United Therapeutics Corporation, a biotechnology company, focuses on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product is Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Ch14.18 MAb, an antibody that is under Phase III clinical trails for the treatment of neuroblastoma; Beraprost 314d, which is under Phase II clinical trails for the treatment of PAH; and 8H9 MAb, an antibody that is under Phase I clinical trail for the treatment of metastatic brain cancer. Further, the company is involved in the early pre-clinical stage of developing TransCon Treprostinil, TransCon Beraprost, and PLacental eXpanded cells for the treatment of PAH; glycobiological antiviral agents for the treatment of infectious diseases, such as Hepatitis C; and engineered lungs and lung tissue, which can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
united therapeutics corp (UTH) Top Compensated Officers
united therapeutics corp (UTH) Key Developments
United Therapeutics Corporation announced consolidated unaudited earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenues of $245,136,000 against $204,214,000 a year ago. Income before income taxes was $90,835,000 against $103,936,000 a year ago. Net income was $62,325,000 against $70,760,000 a year ago. Net income per diluted common share was $1.19 against $1.29 a year ago. Earnings before non-cash charges for the quarter ended March 31, 2013 were $138.649 million, compared to $114.446 million for the same quarter in 2012. Earnings before non-cash charges per diluted share were $2.65 against $2.08 a year ago. The company reaffirmed its 2013 full-year revenue guidance for three commercial products (Remodulin, Tyvaso and Adcirca), as the company continue to expects related revenues to fall within a range of 5% above or below $1.0 billion for 2013.
United Therapeutics Corporation, Q1 2013 Earnings Call, Apr 25, 2013
United Therapeutics Corporation announced that they will report Q1, 2013 results at 9:00 AM, Eastern Standard Time on Apr 25, 2013
| Recently Viewed | |||
| UTH:GR | €52.66 EUR | -0.55 |  |
| Company | Last | Change |
| Actelion Ltd | SFr.58.70 CHF | -0.10 |
| Gilead Sciences Inc | $56.47 USD | +0.73 |
| GlaxoSmithKline PLC | 1,742 GBp | +20.50 |
| Nippon Shinyaku Co Ltd | ¥1,710 JPY | -16.00 |
| Teva Pharmaceutical Industries Ltd | $40.21 USD | +0.02 |
| View Industry Companies | ||
Industry Analysis
UTH
Industry Average
| Valuation | UTH | Industry Range |
| Price/Earnings | 12.1x |
|
| Price/Sales | 3.6x |
|
| Price/Book | 3.0x |
|
| Price/Cash Flow | 11.4x |
|
| TEV/Sales | 2.5x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Northglenn, CO | Office DepotPosted: Mar 01
Sponsored Financial Commentaries
Sponsored Links
To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
